08:23 AM EDT, 03/21/2024 (MT Newswires) -- Merck ( MRK ) said that a phase 3 trial of its Keytruda combined with Lynparza as a potential treatment for metastatic nonsquamous non-small cell lung cancer failed to meet its primary endpoints of overall survival and progression-free survival.

Merck ( MRK ) said the safety profiles of the Keytruda and Lynparza combination in the trial were "consistent with those observed in previously reported studies" for the drugs. A full evaluation of the data from the study is ongoing, Merck ( MRK ) said.

"These results are an important reminder of how challenging it may be to treat these patients with metastatic nonsquamous non-small cell lung cancer," said Gregory Lubiniecki, Merck ( MRK ) vice president for global clinical development.

Price: 123.9, Change: +0.04, Percent Change: +0.04